To evaluate the effect of the administration of Rapamune on a clinical composite variable (change in proteinuria, blood pressure and hematuria) in patients with IgA nephropathy with poor prognosis criteria at month 12th [clinicaltrials_resource:817f37f759785fae1c0fa7ff13a9244b]
sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
To evaluate the effect of the administration of Rapamune on a clinical composite variable (change in proteinuria, blood pressure and hematuria) in patients with IgA nephropathy with poor prognosis criteria at month 12th [clinicaltrials_resource:817f37f759785fae1c0fa7ff13a9244b]
sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
Bio2RDF identifier
817f37f759785fae1c0fa7ff13a9244b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:817f37f759785fae1c0fa7ff13a9244b
measure [clinicaltrials_vocabulary:measure]
To evaluate the effect of the ...... y with poor prognosis criteria
time frame [clinicaltrials_vocabulary:time-frame]
at month 12th
description
sirolimus starting at 1 mg/d ( ...... orvastatin starting at 10 mg/d
identifier
clinicaltrials_resource:817f37f759785fae1c0fa7ff13a9244b
title
To evaluate the effect of the ...... ognosis criteria at month 12th
@en
type
label
To evaluate the effect of the ...... f37f759785fae1c0fa7ff13a9244b]
@en